Antimicrobial Science

Biofilm Efficacy Testing

Evaluate antimicrobial performance against biofilms using controlled growth, treatment, validated recovery, and culture enumeration.

We run grow-and-treat biofilm studies with quantified endpoints to inform formulation decisions, method selection, and EPA-facing claim substantiation.

ISO 17025ASTM E2647ASTM E2799EPA OPPReviewed 2026-05-16
Request a quoteSubmit a sample

Purpose & when to use

Biofilm Efficacy Testing measures how antimicrobials perform against attached microbial communities grown in coupon, reactor, or well-plate systems. Before testing, we define maturation time, treatment exposure, neutralization, disruption, recovery, and culture enumeration. Defining these conditions allows log10 reduction to be interpreted under ISO 17025 controls and within ASTM E2647, ASTM E2799, ASTM E2871, or EPA OPP claim contexts. Use this service when:

  1. EPA OPP claim substantiation for treated surfaces needs biofilm-specific log10 reduction rather than planktonic or simple carrier data.
  2. ASTM E2799 MBEC screening compares formulations, active levels, and contact times before larger EPA OPP programs expand.
  3. ASTM E2647 drip-flow studies evaluate low-shear biofilms on coupons for coatings, hard surfaces, or device materials.
  4. ASTM E2871 disinfectant studies need mature reactor-grown biofilm with defined neutralization, disruption, and culture recovery.
  5. ISO 17025 quality records are required for technical files, R&D gates, or EPA-facing antimicrobial performance packages.

Biofilm efficacy testing is appropriate when the decision depends on performance against an established biofilm structure, not only a fresh inoculum or suspension exposure. Before selecting a method, we connect the organism, maturation model, substrate, treatment condition, recovery method, and reporting threshold to the decision the study needs to support.

Surfaces and biofilm-prone products served

Biofilm studies serve products where attached growth, treatment access, and recovery affect antimicrobial claims under ISO 17025, ASTM, and EPA OPP frames.

  • Treated surfacesHard surfaces and coupons
  • CoatingsAntimicrobial films and finishes
  • DisinfectantsLiquids, foams, gels, wipes
  • Device surfacesMaterials exposed to contamination
  • MaterialsPolymers, metals, glass, ceramics

Instrumentation & measurement ranges

We choose the platform based on the biofilm model, organism, substrate, maturation time, treatment format, and the claim or screening decision.

1 - 30 dmaturation

Coupon and reactor biofilm growth systems

CDC-style, drip-flow, coupon, or plate-based systems generate controlled biofilms with baseline-load checks before treatment exposure.

6 - 96 wellformat

MBEC and well-plate challenge workflow

Peg-lid or well-plate formats support concentration mapping, contact-time screening, and replicate comparison before larger coupon studies.

1 - 10 xdilution series

Neutralization and disruption recovery

Neutralizer effectiveness, toxicity checks, vortexing, sonication, scraping, or extraction workflows verify recovery from biofilm matrices.

1 - 8 LRVreduction

Culture enumeration and calculation review

Serial dilution, plating, incubation, colony counting, and calculation review produce baseline load, survivor counts, and log10 reduction.

Test method options

MethodStrengthsTradeoffAligned with
Drip-flow coupon biofilm efficacy (ASTM E2647 aligned)
  • ASTM E2647 supports low-shear coupon biofilms for treated surfaces and coatings.
  • ISO 17025 records document maturation, exposure, recovery, and enumeration controls.
Maturation acceptance checks add run time before treatment comparisons begin.
ASTM E2647ISO 17025
MBEC concentration mapping (ASTM E2799 aligned)
  • ASTM E2799 MBEC format screens actives, concentrations, and contact times efficiently.
  • Replicate well layouts support early formulation ranking before coupon studies expand.
Well-plate geometry may not represent final product surfaces or application formats.
ASTM E2799
Reactor-grown disinfectant challenge (ASTM E2871 aligned)
  • ASTM E2871 supports disinfectant efficacy against mature reactor-grown biofilm.
  • Defined disruption and neutralization steps improve interpretation of recovered survivors.
Reactor setup and organism growth behavior can increase scheduling variability.
ASTM E2871
EPA OPP claim-context biofilm study
  • EPA OPP framing connects log10 reduction outputs to antimicrobial claim language.
  • Protocol acceptance criteria align controls, organisms, substrates, and contact times.
Claim-oriented studies require predefined criteria and full control review before testing.
EPA OPP

Setup configurations

Each biofilm efficacy study is scoped around the organism, growth model, substrate, maturation time, treatment format, contact time, neutralizer chemistry, and recovery behavior. Before testing, we define baseline-load acceptance, replicate count, untreated controls, recovery validation, and the decision threshold. That planning ties each log-reduction value to the intended claim or formulation comparison.

Sample matrix

Disinfectant, sanitizer, wipe liquid, foam, gel, coating, treated coupon, or device material documented by lot, active level, preparation, and storage condition.

Exposure profile

Biofilm model, organism, substrate, maturation time, treatment volume, contact time, temperature, soil load, and hard-water condition fixed before study start.

Media & handling

Growth medium, incubation condition, rinse steps, neutralizer, disruption method, dilution scheme, plating method, and incubation parameters selected to control recovery bias.

Sample numbers

Replicate coupons or wells, untreated controls, growth controls, neutralizer controls, toxicity controls, and blanks sized to the method and claim frame.

Chain of custody

Sample receipt, biofilm growth records, exposure timing, media lots, environmental logs, deviations, and final calculations retained with the report package.

Methods anchored to the standards that matter

The labels below distinguish ARE Labs' accredited laboratory system from the aligned biofilm methods and EPA OPP claim frames. They also match the accreditation and alignment labels shown in the page header.

  • ISO 17025AccreditedLaboratory competence, traceability, documented methods, and quality-system controls.
  • ASTM E2647AlignedDrip-flow biofilm growth and coupon handling for low-shear models.
  • ASTM E2799AlignedMBEC well-plate screening for biofilm antimicrobial susceptibility.
  • EPA OPPAlignedAntimicrobial product claim context and substantiation expectations.

Key data outputs & reporting

Biofilm efficacy studies report log10 reduction or percent reduction by organism, substrate, maturation time, treatment condition, and recovery workflow. The report places baseline biofilm load, untreated controls, neutralization checks, recovery validation, replicate statistics, and detection limits alongside the efficacy result. This context helps technical reviewers distinguish antimicrobial effects from growth variability, treatment carryover, matrix interference, or extraction bias.

Primary outputs

  • Log10 reduction or percent reduction versus untreated biofilm controls for each organism, substrate, maturation time, and condition.
  • Baseline biofilm load, run qualification, and acceptance checks showing whether each challenge met protocol criteria.
  • Neutralization effectiveness, toxicity-control, and recovery validation summaries for each product or substrate family.
  • Replicate statistics including mean, SD, CV, detection limit, and flagged deviations where comparison is supported.
  • Condition comparisons across active level, contact time, soil load, hard water, substrate, or application format.

Deliverables

#FormatContents
01PDF reportMethods, controls, log-reduction tables, QA / QC notes, and interpretation limits.
02CSV / XLSX datasetsRaw counts, dilution factors, calculations, controls, and replicate statistics.
03FiguresBiofilm reduction summaries across products, contact times, or substrates.

QA / QC & data integrity

Biofilm results are defensible only when growth consistency, treatment timing, neutralization, disruption, recovery, and enumeration are controlled together. Each study includes documented controls under the ISO 17025 quality system. Before finalizing log-reduction results for EPA-facing or internal decisions, we review baseline-load acceptance and the recovery evidence for the run.

Baseline biofilm acceptance checks verify control load before treatment results are interpreted.

Growth controls and contamination checks separate product effect from run failure or handling artifacts.

Neutralization effectiveness and toxicity controls confirm the stop solution works without suppressing recovery.

Recovery validation documents disruption or extraction performance for each substrate or biofilm matrix.

Replicate calculations report mean, SD, CV, detection limits, and acceptance-limit exceptions where applicable.

Chain-of-custody, timing logs, media lots, incubation records, and deviations are retained with the final package.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These questions often arise when disinfectant manufacturers, coating teams, treated-material developers, and medical-device groups plan biofilm efficacy studies. They cover model selection, maturation time, recovery validation, testing of wipes and foams, optional imaging, deliverables, and when to use MBEC or coupon methods. The answers are starting points. Contact us if your organism, surface, product format, or EPA OPP claim context falls outside the examples described here.

Q.Are biofilms always harder to kill?
A.Often, yes. Biofilm structure and matrix material can make attached communities more tolerant than planktonic cells. When that difference matters to a product claim or formulation decision, we test mature, attached communities.
Q.How do you keep biofilm growth consistent?
A.We define the organism, medium, substrate, incubation condition, maturation time, and baseline-load acceptance criteria before testing. If a run misses the control criteria, we document the issue before interpreting the results or deciding whether to repeat the run.
Q.Can you test wipes, foams, or gels on biofilms?
A.Yes, when the method is fit for purpose. We set the application method, contact time, neutralizer, and recovery workflow for the product format so survivor counts reflect treatment performance.
Q.Which biofilm method should we choose?
A.Method choice depends on the claim, surface, organism, shear condition, and study phase. MBEC often supports early screening, while coupon or reactor models are generally a better match for surface claims.
Q.Do you provide imaging outputs?
A.Optional imaging can help interpret attachment, coverage, or treatment effects. Culture enumeration remains the primary quantitative endpoint for calculating log10 reduction.
Q.What do we receive after testing?
A.You receive a PDF report and CSV or XLSX tables with raw counts, dilution factors, log10 reductions, control results, recovery data, replicate statistics, and interpretation limits.

Standards & guidance

ARE Labs plans biofilm efficacy studies around laboratory competence, controlled growth models, MBEC screening, reactor-grown biofilm challenges, and EPA OPP performance expectations. ISO 17025 anchors the accredited laboratory system. ASTM E2647, ASTM E2799, ASTM E2871, and EPA OPP provide aligned method or claim frames when they fit the organism, substrate, study design, and claim context.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, documented methods, traceability, and quality-system controlsView standard ->Surface Antimicrobial - Aligned

ASTM E2647

Drip-flow reactor biofilm growth and coupon handling under low-shear conditionsView standard ->Surface Antimicrobial - Aligned

ASTM E2799

MBEC biofilm antimicrobial susceptibility screening using well-plate or peg-lid formatsView standard ->Surface Antimicrobial - Aligned

ASTM E2871

Disinfectant efficacy against biofilm grown in reactor systems with defined recoveryView standard ->Antimicrobial Claims - Aligned

EPA OPP

Antimicrobial product performance expectations for EPA-facing claim substantiationView standard ->

Related services & devices

Service

Carrier-Based Surface Efficacy

Carrier studies help bridge simple surface efficacy data to the more demanding biofilm growth and recovery model.Read more ->Devices

Surface Antimicrobial Products

Treated materials, coatings, and disinfectants use biofilm data when attached growth affects the claim.Read more ->Service

Time-Kill Kinetics (Surface / Liquid)

Kinetics studies map concentration and contact-time response before biofilm-specific methods are selected.Read more ->Devices

Medical Devices

Device surfaces and materials may need biofilm recovery evidence when contamination risk drives design decisions.Read more ->